While promoter methylation levels of NUPR1 and GLI1 genes had not been previously investigated in this context, our findings revealed that promoter hypermethylation of NUPR1 and MGMT genes may confer a better prognosis to GBM patients, while promoter hypermethylation of GLI1 and NDRG2 genes may confer a worse prognosis to GBM patients. This evidence concerns the gene MGMT and glioblastoma.